Chronic Kidney Disease – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of CKD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total prevalence of CKD for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and the other countries covered in this report. In addition to forecasting the total prevalent patient population, we estimate the number of drug-treatment opportunities in the mature markets.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology’s CKD forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with CKD per year?
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with CKD per year?
- How will improvements in survival change the number of people living with a diagnosis of CKD?
- How will the declining risk of recurrence change the number of people diagnosed with CKD per year?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CKD over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following CKD patient populations:
- Total prevalence by stage
- Dialysis status
- Type of dialysis
- Hyperphosphatemia populations
- Moderate hyperkalemia populations
- Severe hyperkalemia populations
- Diagnosed prevalent cases by stage
- Diagnosed drug-treated populations by stage
Note: Coverage may vary by country and region.
Mariah Hamalainen, M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Hamalainen earned her master’s degree in public health epidemiology from Florida International University, where she also worked as a graduate research assistant on an HIV testing and counseling study. She also completed two federally funded public health internships on data analysis and epidemiology. Her areas of interest are infectious diseases and women’s health.